BAUSCH HEALTH COMPANIES INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.6 USD | -0.69% |
|
-4.12% | +7.23% |
Presentation Operator MessageOperator (Operator)Good morning, and welcome to the Bausch Health...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures, and markets a range of products primarily in gastroenterology (GI), hepatology, neurology, dermatology, eye health, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.
Sector
Pharmaceuticals
Calendar
2024-05-01
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
8.6
USD
Average target price
10.33
USD
Spread / Average Target
+20.16%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +7.23% | 3.18B | |
| +27.97% | 676B | |
| +23.58% | 554B | |
| -7.02% | 349B | |
| +14.85% | 318B | |
| +6.25% | 291B | |
| +2.96% | 210B | |
| -0.41% | 204B | |
| -10.02% | 194B | |
| -11.81% | 144B |
- Stock Market
- Equities
- BHC Stock
- News Bausch Health Companies Inc.
- Transcript : Bausch Health Companies Inc., Q2 2022 Earnings Call, Aug 09, 2022
